Brief: Arcellx Announces Robust Responses From Cart-ddBCMA Phase 1 Expansion Trial

Arcellx

09/12/2022 13:55

Dec 9 (Reuters) - Arcellx Inc  ACLX.O :
    * ARCELLX ANNOUNCES CONTINUED ROBUST LONG-TERM RESPONSES
FROM ITS
CART-DDBCMA PHASE 1 EXPANSION TRIAL IN PATIENTS WITH RELAPSED OR
REFRACTORY MULTIPLE MYELOMA AND ADDITIONAL PIPELINE PROGRESS
    * ARCELLX ANNOUNCES CONTINUED ROBUST LONG-TERM RESPONSES
FROM ITS
CART-DDBCMA PHASE 1 EXPANSION TRIAL IN PATIENTS WITH RELAPSED OR
REFRACTORY MULTIPLE MYELOMA AND ADDITIONAL PIPELINE PROGRESS
    * ARCELLX INC - FIRST PATIENTS DOSED IN IMMAGINE-1 PHASE 2
CLINICAL TRIAL WITH PIVOTAL DRUG PRODUCT
    * ARCELLX INC - INITIATED PHASE 1 CLINICAL TRIAL OF ACLX-002
FOR
TREATMENT OF PATIENTS WITH AML/MDS
    * ARCELLX INC - NO CASES OF GRADE >3 CRS AT RP2D AND NO
DELAYED
NEUROTOXICITY OR PARKINSONIAN-LIKE EVENTS
    * ARCELLX INC - INTERIM CART-DDBCMA PHASE 1 CLINICAL RESULTS
DEMONSTRATE DEEP AND DURABLE RESPONSES IN PATIENTS WITH POOR
PROGNOSTIC FACTORS

Source text for Eikon:  ID:nPn4w6Ny8a 
Further company coverage:  ACLX.O 
 ((Reuters.Briefs@thomsonreuters.com;))